Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer’s Disease

Catherine Sharo, Jing Zhang, Tianhua Zhai, Jingxuan Bao, Andrés Garcia-Epelboim, Elizabeth Mamourian, Li Shen, Zuyi HuangTargets 2024 · DOI

TL;DR

This study tackles the urgent need for new Alzheimer's disease (AD) treatments by exploring drug targets involved in brain inflammation. By combining computational druggability analysis with single-nuclei sequencing and molecular docking, the researchers identified promising FDA-approved drugs that could be repurposed to combat AD-related neuroinflammation.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a growing public health crisis with limited effective treatments. Current FDA-approved drugs primarily manage symptoms, rather than halting disease progression or offering a cure. A key area of interest is the link between AD pathology and brain inflammation. As AD progresses, neuronal damage and the accumulation of amyloid-beta plaques and tau tangles trigger inflammatory responses. This neuroinflammation can, in turn, exacerbate neuronal death and disease severity. Therefore, identifying and validating protein targets that are central to both AD and brain inflammation, and are also "druggable" (meaning they can be effectively targeted by small molecules), is crucial for developing new therapeutic strategies.

Methods

The researchers employed a multi-pronged computational approach:

  • Druggability Analysis:
    • Structure-based methods:
      • Drug-Like Density (DLID): This method, implemented using Molsoft ICM PocketFinder, assesses protein pockets for features like volume, hydrophobicity, and buriedness to predict their potential to bind drug-like molecules. A DLID score above 0.5 was considered a benchmark for druggability.
  • SiteMap: This tool from Schrodinger provides SiteScore and DScore, which evaluate binding site characteristics and druggability, respectively. The DScore was prioritized for its focus on distinguishing druggable from undruggable targets.
  • Sequence-based method: * SPIDER: This machine-learning approach uses protein sequences to predict the likelihood of a target being druggable.
  • Single-Nuclei RNA Sequencing (snRNA-seq): Data from entorhinal and prefrontal cortex tissues of AD patients and healthy controls were analyzed to identify cell-type-specific gene expression patterns of potential inflammation targets, validating their clinical relevance in AD.
  • Small Molecule Docking: For the most promising druggable targets, molecular docking simulations were performed using FDA-approved drugs to predict their binding affinity and potential as inhibitors.

Datasets

  • Protein Data Bank (PDB): Used for obtaining protein structures for structure-based druggability analysis.
  • ssREAD portal: Provided single-nuclei RNA-sequencing data (GSE138852 and GSE147528) from human entorhinal and prefrontal cortex tissues of AD and healthy individuals.
  • FDA-approved drug library: A set of approximately 2,500 FDA-approved drugs was used for small molecule docking.

Key Insights and Ideas

  • Inflammation as a key therapeutic avenue: The study reinforces the critical role of brain inflammation in AD pathogenesis and highlights it as a promising area for therapeutic intervention.
  • Multi-method druggability assessment is crucial: Relying on a single method for druggability prediction can be misleading. Combining structure-based and sequence-based approaches, and then normalizing their results, provides a more robust ranking of potential targets.
  • Not all "druggable" targets are equal: Even if a protein pocket is predicted to be druggable, its role in essential biological pathways needs careful consideration. Early-stage complement pathway proteins, for instance, were deemed less ideal for inhibition due to potential broad immunosuppressive effects.
  • Drug repurposing offers a faster path to treatment: Identifying existing FDA-approved drugs that can target AD-related inflammation significantly accelerates the drug development pipeline compared to discovering entirely new compounds.

Key Results

  • Top Druggable Targets Identified: The study identified DRD2, C9, C4b, C5AR1, and GABA-A-R as the most druggable targets involved in AD-related inflammation.
  • Validation through snRNA-seq: Single-nuclei sequencing data confirmed the clinical relevance of these targets by showing differential expression patterns in AD brains, particularly in neurons and endothelial cells. For example, GABRA1 was downregulated in neurons, while CD59 was upregulated, indicating increased complement activation.
  • FDA-Approved Drug Candidates: Molecular docking identified multiple FDA-approved drugs with decent binding affinities for the top targets.
  • DRD2 had 8 potential inhibitors.
  • C4b had 10 potential inhibitors.
  • GABA-A-R had 28 potential inhibitors.
  • C9 had 89 potential inhibitors.
  • C5AR1 had 131 potential inhibitors.
  • Promising Repurposing Candidates: Two drugs, v316 (paracetamol) and C15H14N2O2, emerged as top contenders, showing good binding scores for multiple targets (v316 for C4B and C9; C15H14N2O2 for C5AR1 and C9).

Limitations and Future Work

  • Limitations:
    • The study relied on X-ray crystal structures for druggability analysis. Cryo-EM structures, which can be valuable for visualizing flexible proteins, were not always available or had lower resolutions.
  • Early-stage complement pathway proteins (C1QB, C1R, C3) were excluded from docking due to concerns about broad immunosuppressive effects.
  • The binding scores from docking represent static interactions, which may not fully capture dynamic binding stability.
  • Future Work:
    • Incorporate cryo-EM structures as they become available to assess potential structural differences influencing druggability.
  • Conduct detailed molecular dynamics (MD) simulations to assess dynamic binding stability and further differentiate compounds.
  • Perform experimental validation of the top-performing drug candidates to confirm their efficacy against the identified protein targets.
  • Explore the potential of early-stage complement proteins as drug targets with careful consideration of immune-related side effects.
  • Conduct in vitro experiments to determine if the identified inhibitors actually affect the protein targets.

Summary updated

Abstract

Alzheimer's disease is a neurodegenerative disease that continues to have a rising number of cases. While extensive research has been conducted in the last few decades, only a few drugs have been approved by the FDA for treatment, and even fewer aim to be curative rather than manage symptoms. There remains an urgent need for understanding disease pathogenesis, as well as identifying new targets for further drug discovery. Alzheimer's disease (AD) is known to stem from a build-up of amyloid beta (Aβ) plaques as well as tangles of tau proteins. Furthermore, inflammation in the brain is known to arise from the degeneration of tissue and the build-up of insoluble material. Therefore, there is a potential link between the pathology of AD and inflammation in the brain, especially as the disease progresses to later stages where neuronal death and degeneration levels are higher. Proteins that are relevant to both brain inflammation and AD thus make ideal potential targets for therapeutics; however, the proteins need to be evaluated to determine which targets would be ideal for potential drug therapeutic treatments, or 'druggable'. Druggability analysis was conducted using two structure-based methods (i.e., Drug-Like Density analysis and SiteMap), as well as a sequence-based approach, SPIDER. The most druggable targets were then evaluated using single-nuclei sequencing data for their clinical relevance to inflammation in AD. For each of the top five targets, small molecule docking was used to evaluate which FDA approved drugs were able to bind with the chosen proteins. The top targets included DRD2 (inhibits adenylyl cyclase activity), C9 (binds with C5B8 to form the membrane attack complex), C4b (binds with C2a to form C3 convertase), C5AR1 (GPCR that binds C5a), and GABA-A-R (GPCR involved in inhibiting neurotransmission). Each target had multiple potential inhibitors from the FDA-approved drug list with decent binding infinities. Among these inhibitors, two drugs were found as top inhibitors for more than one protein target. They are C15H14N2O2 and v316 (Paracetamol), used to treat pain/inflammation originally for cataracts and relieve headaches/fever, respectively. These results provide the groundwork for further experimental investigation or clinical trials.
BibTeX
@inproceedings{sharo2024repurposing,
  author = {Catherine Sharo and Jing Zhang and Tianhua Zhai and Jingxuan Bao and Andrés Garcia-Epelboim and Elizabeth Mamourian and Li Shen and Zuyi Huang},
  title = {{Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer’s Disease}},
  booktitle = {Targets},
  year = {2024},
  doi = {10.3390/targets2040025},
}
Figure